Optimi Health Celebrates Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial
14. September 2023 14:59 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, is pleased...
Optimi Health To Supply MDMA For Therapist Experiential Training Program at Numinus, Supported by MAPS
15. Juni 2023 09:40 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, June 15, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator...
Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick Doblin at Its Drug Development Lab
29. März 2023 13:41 ET
|
Psycheceutical Bioscience, Inc.
Psycheceutical Chief Visionary Officer Zappy Zapolin and CEO Chad Harman with MAPS Founder Rick Doblin MIAMI, March 29, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. ("Psycheceutical"...
Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health
16. August 2022 09:00 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health...